Overview

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

Status:
Completed

Trial end date:
2016-07-25

Target enrollment:

Participant gender:

Summary

The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD. Additionally, the effect of the behavioural intervention on top of aclidinium bromide/formoterol fumarate 400/12 μg will be assessed both on the exercise endurance and the physical activity.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Menarini Group

Treatments:

Bromides
Formoterol Fumarate